Brief: Rapport Therapeutics Announces Positive Topline Results From Its Phase 2 Trial Of Rap-219 For The Treatment Of Bipolar Mania
Tue 11:01
BRIEF-Rapport Therapeutics Announces Positive Topline Results From Its Phase 2 Trial Of Rap-219 For The Treatment Of Bipolar Mania Oct 20 (Reuters) - Rapport Therapeutics, Inc. RAPP.O:
RAPPORT THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 2 TRIAL OF RAP-219 FOR THE TREATMENT OF BIPOLAR MANIA
RAPPORT THERAPEUTICS - RAP-219 ACHIEVES 3.1-POINT PLACEBO-ADJUSTED IMPROVEMENT IN YMRS AT WEEK 3
RAPPORT THERAPEUTICS - RAP-219-TREATED PATIENTS HAD 15.4-POINT MEAN REDUCTION IN YMRS AT WEEK 3
RAPPORT THERAPEUTICS - RAP-219 WELL TOLERATED WITH ONLY MILD OR MODERATE ADVERSE EVENTS
RAPPORT THERAPEUTICS - PLANS FDA MEETING IN Q1 2027 FOR RAP-219 PHASE 3 TRIAL DESIGN
RAPPORT THERAPEUTICS - TWO PHASE 3 TRIALS OF RAP-219 IN BIPOLAR MANIA EXPECTED TO START IN H2 2027
Source text: ID:nGNX3JRS0r
Further company coverage: RAPP.O
((Reuters.Briefs@thomsonreuters.com;))